

GUIDELINES FOR REVIEW AND APPROVAL OF CLINICAL TRIALS

APRIL, 2023

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

GUIDELINES DEVELOPMENT HISTORY

DRAFT ZERO	16/04/2021
ADOPTION BY RWANDA FDA	18/05/2021
STAKEHOLDERS CONSULTATION	18/06/2021
ADOPTION OF STAKEHOLDERS' COMMENTS	30/06/2021
DATE FOR COMING INTO EFFECT	11/04/2023

DOCUMENT REVISION HISTORY

Date of	Revision	Changes made and/or reasons for revision	
revision	number		
16/07/2021	0	First issue	
03/04/2023	01	 The reference number was changed from DIS/GDL/042 to No FDISM/PVSM/GDL/001 Rev_2 as per the current SOP on document control 	
		2. Timelines for review during emergencies was revised as per AVAREF recommendations;	
		3. Components on review of safety handling were removed;	
		4. Criteria for accepting GMPs for imported IPs were included;	
		5. Statement for review by the technical committee was included;	
		6. Templates of the AVAREF were adopted;	
		 Necessary editorial changes in line with SOP on document control were included. 	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

FOREWORD

Rwanda Food and Drugs Authority (Rwanda FDA) is a regulatory body established by Law N° 003/2018 of 09/02/2018, specifically in article 8, paragraph 7 and 12 with a mandate to regulate and inspect clinical trials in Rwanda. Reference is made to the provisions of the technical regulation N° FDISM/PVSM/TGR/001 Rev_2 governing the conduct of clinical trials, the Authority issues *Guidelines N° FDISM/PVSM/GDL/008 Rev_1* for review and approval of clinical trials.

These guidelines have been developed to provide a model of review of clinical trials to ensure compliance with sound scientific aspects and regulatory requirements prior to approval and authorization by the Authority.

These guidelines were developed in reference to the existing guidelines of the World Health Organization (WHO) and the International Conference on Harmonization of Technical Requirements for Good Clinical Practices (ICH E6) and other available literature.

The Authority acknowledges all the efforts of key stakeholders who participated in the development and validation of these guidelines.

Dr. Emile BIENVENU Director General

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

TABLE OF CONTENTS

GUIDELINES DEVELOPMENT HISTORY	2
DOCUMENT REVISION HISTORY	2
FOREWORD	3
TABLE OF CONTENTS	
ACCRONYMES AND ABBREVIATIONS	5
GLOSSARY	6
1.0. INTRODUCTION	.10
2.0. SCOPE	.10
3.0. REVIEW OF CLINICAL TRIAL APPLICATIONS	.10
3.1 Screening of Clinical Trial applications	.10
3.2 Review of Clinical Trial Applications	.11
3.3 Timelines for review of Clinical Trial Applications	
3.4 Types of clinical trial reviews	.12
3.4.1 Routine review of Clinical Trial Applications	.12
3.4.2 Non-routine reviews of clinical trial application	.12
3.5 Review of additional data & updates on clinical Applications	.13
3.6 Review of quality, non-clinical and clinical data	.13
3.6.1 Quality Review of investigational product (s)	.14
3.6.2 Review of non-clinical data	.14
3.6.3 Review of Clinical Data	
3.7 Statistical Review of Clinical trial application	.15
3.8 General review report for Clinical Trial Applications	
4.0. REVIEW OF AMENDMENTS AND RENEWAL OF CLINICAL TRIAL	.16
5.0. CLINICAL TRIAL APPROVAL PROCESS	
5.1 Clinical trial registration	
5.2 Publication and maintenance of clinical trial register	
6.0. POST TRIAL PROTOCOL REVIEW	.17
ENDORSEMENT OF TE GUIDELINES	.18
ANNEXES	.19
ANNEX-I: CTA REVIEW PROCESS FLOW CHART	.20
ANNEX-II: Template for Screening of clinical trial application	.21
ANNEX-III: Template for review of clinical trial application	
ANNEX-IV: Template of clinical trial approval certificate	.37
ANNEX-V: Template of clinical trial approval certificate for renewal	.39
ANNEX-VI: Template of additional data or query response	.41
ANNEX-VII: Template for Investigational Product Quality Review	.44
ANNEX-VIII: Template for review of non-clinical data	.54
ANNEX-IX: Template for Review of trial amendment	.61

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ACCRONYMES AND ABBREVIATIONS

AE:	Adverse Event
API:	Active pharmaceutical Product
AVAREF:	African Vaccine Regulatory Forum
CIOMS:	Council of International Organization for Medical Science
CRO:	Contract Research Organization
CRF:	Case report form
CTA:	Clinical Trial Application
CTA-A:	Clinical Trial Application for Amendment
EUAL:	Emergency Use Assessment and Listing Procedure
GMP:	Good Manufacturing Practice
ICH:	International Conference on Harmonization
ICFs:	Informed Consent Forms
IRB:	Institutional Review Board
MTA:	Material Transfer Agreement
NDA:	New Drug Application
PI:	Principal Investigator
RNEC :	Rwanda National Research Ethics Committee
Rwanda FDA	Rwanda Food and Drugs Authority
SAE:	Serious Adverse Event
SmPC:	Summary of product characteristics
SUSARs:	Suspected Unexpected Serious Adverse
WHO:	World Health Organisation

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

GLOSSARY

In these guidelines:

"An applicant" means the Sponsor or Principal Investigator. The applicant shall therefore be responsible for signing the application form.

"Authority" Means Rwanda Food and Drugs Authority or its acronym "Rwanda FDA", established by the Law N° 003/2018 of 09/02/2018.

"Amendment" A written description of a change(s) to or formal clarification of a protocol.

"Applicable Regulatory Requirement(s)" Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

"Blinding/Masking" A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s). Single-blinding usually refers to the participant(s) being unaware; and double-blinding usually refers to the participant(s), investigator(s), monitor, and, in some cases, data analyst(s) being unaware of the treatment assignment(s).

"Child" A person who is below eighteen (18) years of age or the definition of child as defined in the laws currently enforced in Rwanda.

"Case Report Form" A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each study participant.

"Clinical Trial" Any investigation in human study participants intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s) and/or to identify any adverse reactions to an investigational product(s) and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

"Clinical Trial Report" A written description of a trial/ study of any therapeutic, prophylactic or diagnostic agent conducted in human study participants in which the clinical and statistical description, presentations and analyses are fully integrated into a single report.

-"*Data and Safety Monitoring Board*" An independent data monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data and the critical efficacy endpoints and to recommend to the sponsor whether to continue, modify, or stop a trial.

"Documentation" All records, in any form (including, but not limited to, written, electronic, magnetic, and optical records, and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

"Essential Documents" Documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced.

"Ethical Clearance" An authorization to conduct a clinical trial issued by the Rwanda National Research Ethics Committee (RNEC) or Institutional Review Boards (IRB) based on ethical issues related to trials involving human participants in Rwanda.

"Good Clinical Practice" A standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provide assurance that the data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial/study participants are protected.

"Good Manufacturing Practice (GMP)" The part of pharmaceutical quality assurance which ensures that products are consistently produced and controlled to quality standards appropriate to their intended use and as required by the marketing authorization.

"Impartial witness" A person, who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the participant or the participant's legally acceptable representative cannot read, and who reads the Informed Consent Form and any other written information supplied to the participant.

"Informed Consent" A process by which a study participant voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the study participant's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.

'Investigational Product" A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.

"Investigator" A physician, dentist or other qualified person who conducts a clinical trial at a trial site. See also Sub-investigator.

"Investigator's Brochure" A compilation of the clinical and non-clinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human study participants.

"Legal representative" The name given to describe the executor, administrator or the person who looks after another person's affairs.

"Materials Transfer Agreement" An MTA is a written contract that governs the transfer of tangible research materials or biological samples between parties.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

"Multi-centre Trial" A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator.

"Phase I trials" These are first trials of a new active ingredient or new formulations in man, often carried out in healthy volunteers. Their purpose is to establish a preliminary evaluation of safety, and a first outline of the pharmacokinetic and, where possible, a pharmacodynamic profile of the active ingredient in human.

"Phase II trials" These trials are performed in a limited number of study participants and are often, at a later stage, of a comparative (e.g. placebo-controlled) design. Their purpose is to demonstrate therapeutic activity and to assess short-term safety of the active ingredient in patients suffering from a disease or condition for which the active ingredient is intended. This phase also aims at the determination of appropriate dose ranges or regimens and (if possible) clarification of dose-response relationships in order to provide an optimal background for the design of extensive therapeutic trials.

"Phase III trials" Trials in larger (and possibly varied) patient groups with the purpose of determining the short and long-term safety/efficacy balance of formulation(s) of the active ingredient, and of assessing its overall and relative therapeutic value. The pattern and profile of any frequent adverse reactions must be investigated and special features of the product must be explored (e.g. clinically-relevant investigation medicinal product interactions, factors leading to differences in effect such as age). These trials should preferably be of a randomized double-blind design, but other designs may be acceptable, e.g. long-term safety studies. Generally, the conditions under which these trials are carried out should be as close as possible to normal conditions of use.

"Phase IV studies" Studies performed after marketing of the pharmaceutical product. Trials in phase IV are carried out on the basis of the product characteristics on which the marketing authorization was granted and are normally in the form of post-marketing surveillance, or assessment of therapeutic value or treatment strategies. Although methods may differ, these studies should use the same scientific and ethical standards as applied in pre-marketing studies. After a product has been placed on the market, clinical trials designed to explore new indications, new methods of administration or new combinations, etc. are normally considered as trials for new pharmaceutical products.

"Placebo" An inactive substance or sham form of a therapy administered as a control in testing experimentally or clinically the efficacy of a biologically active preparation or procedure.

"Pre-clinical Studies" Biomedical studies not performed on human study participants.

"Principal Investigator" A person responsible for the conduct of the clinical trial at a trial site who is a physician, dentist or other qualified person, resident in Rwanda and a member of good standing of a professional body. If a trial is conducted by a team of individuals at a trial site, the principal investigator is the responsible leader of the team. See also Sub-investigator.

"Protocol" A document that describes the objective(s), design, methodology, statistical considerations and organization of a trial. The protocol usually also gives the background and rationale for the trial but these could be provided in other protocol referenced documents.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

"Protocol Amendment" A written description of change(s) to or formal clarification of a protocol.

"Randomization" The process of assigning trial study participants to treatment or control groups using an element of chance to determine the assignments in order to reduce bias.

"Source Data" All information in original records and certified copies of original records of clinical findings, observations or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies).

"Sponsor" An individual, company, institution or organization which takes responsibility for the initiation, management and/or financing of a clinical trial.

"Standard Operating Procedures (SOP)" Detailed written instructions to achieve uniformity of the performance of a specific function.

"*Substantial amendment*": means change to the terms of the protocol or any other trial supporting documentation that is likely to have significant impact and affect the safety and integrity of trial participants, the scientific value of the research, the conduct or management of the research, and the quality or safety of any investigational medicinal product used in research.

"Trial Site" The location(s) where trial-related activities are actually conducted.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

1.0. INTRODUCTION

Clinical trials are planned scientific investigations conducted on humans and animals to gather information on safety and efficacy of medical products and health technologies. Such experiments involve the administration of investigational products in patients, healthy volunteers or animal species to generate data that can later be used for marketing authorization of a product.

These guidelines highlight the clinical trial review process of submitted clinical trial data to be submitted to the Authority for further authorization to conduct clinical trials in Rwanda. Good Clinical Practice (GCP) principles and other ethical considerations with the aim of ensuring the safety and protection of trial participants in Rwanda.

2.0. SCOPE

These guidelines apply to the review of all scientific aspects and regulatory requirements for initial clinical trial application, additional data if applicable, amendments, clinical trial reports including progress, close out and safety reports.

These guidelines cover the review of Clinical Trial Application (CTA) of both unregistered or registered investigational products which include pharmaceutical products, vaccines and other biological products, herbal medicines, cosmetics, medical devices and in vitro diagnostics with new intended uses.

3.0. REVIEW OF CLINICAL TRIAL APPLICATIONS

The Clinical Trial Applications (CTAs) and Clinical Trial Application amendments (CTAAs submitted to the authority are not considered valid until they have been screened for completeness. All applications for clinical conduct in Rwanda shall undergo screening and full assessment with exception of applications submitted using reliance pathways which may be waived from full assessment. In this case, the review process shall focus on regulatory requirements, review reports and decisions from other regulatory Authorities or joint review.

3.1 Screening of Clinical Trial applications

On receipt of Clinical Trial Application (CTA) or Clinical Trial Applications for amendment (CTA-A), the Authority shall assign the reference number to the application which will be communicated with applicant for future correspondences.

The application shall then be screened for completeness and compliance with the regulatory requirements within ten (10) working days from the submission date.

During the screening of CTA/CTAA, the Authority shall record all administrative information related to the application using screening template (ANNEX-I) and a screening report is developed.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

The Clinical Trial Application shall pass the screening stage and be accepted for review if more than 70% of the applicable required documents are provided. This shall include but not be limited to the signed, dated application letter and forms, duly signed protocol, updated IB, proof of payment of applicable fees, declarations and agreement between the sponsor and principal investigator.

In case the applicant has provided incomplete information after screening, the Authority communicates in writing and request missing regulatory requirements.

The applicant submits missing requirements in writing to the Authority within **fifteen (15) working days** unless she/he requests for extension before deadline. Incomplete CTAs will be subjected to resubmission.

3.2 Review of Clinical Trial Applications

The accepted CTAs are subjected to the full review of protocol and its supplementary documents and investigational product dossier in order to assess the quality of the investigational product to ensure that it does not endanger the safety and well-being of clinical trial participants or other persons.

In addition, the Authority undertakes the detailed review of non-clinical data, Chemistry, Manufacturing and Control (CMC) of investigational product(s) using the review template as per **ANNEX-II.** The clinical trial application is subjected to the first and second reviews to increase transparency and quality assurance.

The review of clinical trial applications is undertaken using the same set of criteria regardless of the applicant. The review prioritization follows the first-in first-out rule (FIFO), except for clinical trials that are conducted in public health emergencies such as disease outbreaks, which may be exempted from screening and considered for expedited review.

The CTA/CTAA is reviewed by two different reviewers to ensure transparency and ensure review of safety, efficacy and quality of investigational products. The full review report will be developed using appropriate review templates as per **ANNEX-II or ANNEX VII**. Generally, the initial review of CTAs and CTA-As may result in queries or additional information that needs to be addressed by the applicant. In this situation a communication documenting all deficiencies in the application will be issued to the applicant.

3.3 Timelines for review of Clinical Trial Applications

The routine review of new clinical trial application does not exceed sixty (60) working days. In addition, the Authority may expedite or fast track the review process and approve a clinical trial application within thirty (30) working days according to the circumstances specified in the relevant guidelines.

In the event of public health emergencies, the clinical trial review process shall be conducted and provide approval of clinical trial application in 10 working days for products already registered for other indications and 15 working days for novel products.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

The clinical trial application response to queries or clarifications from the applicant shall not exceed thirty (30) working days unless she/he requests for extension in writing before deadline.

These timelines shall not include the time taken by the applicant to respond to any request for additional information or clarification from the Authority. A stop-clock mechanism shall thus apply each time the Authority requests for additional information. This will help to monitor timelines for each application from the date application to the final approval.

The internal tracking system and a standards operating procedure shall be put in place to monitor compliance with above prescribed timelines for review and approval of clinical trial applications.

3.4 Types of clinical trial reviews

CTAs and CTA-As submitted to the Authority may be subjected to any of the four (4) types of reviews depending on the applicable criteria. After review, the Authority will communicate a list of queries or request for clarifications (if any) to the applicant.

3.4.1 Routine review of Clinical Trial Applications

The routine review of CTA or CTA-As is conducted by the staff within the Authority according to the established procedures and timelines.

3.4.2 Non-routine reviews of clinical trial application

The non-routine review process is a pathway for accelerating the review and approval of clinical trial application by using reliance, fast-track or expedited decision-making (e.g., receipt, screening, evaluation, review, and authorization) under certain circumstances (e.g., public health emergencies).

a) Expert Reviews

The expert reviews of Clinical trials apply when the Authority hires/invites the external reviewers following to the internal procedures depending on the complexity of clinical trial applications that require special expertise. The experts will sign a confidentiality agreement with the Authority to ensure the protection of the clinical trial information.

b) Joint Reviews

The joint reviews of Clinical Trial Applications are carried out jointly by the Authority with other relevant regulatory bodies at national, regional or international level. The applications are reviewed by experts from each participating regulatory body and the coordination is done by a designated regulatory authority. Therefore, a regulatory decision will be taken at national level once all the requirements are fulfilled.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

c) Reliance during review

In case the Authority has received the clinical trial application for the protocol that has been approved by other competent regulatory authorities (ies), regional and/or international bodies, the Authority may rely on review report or valid approval and consider the review of the country specific requirements for avoiding duplication of efforts or waste of resources. The authority reserves rights to request any additional information to ensure the safety and well-being of trial participant is protected.

d) Expedited Reviews

In case of public health emergencies, the Authority may expedite the review of clinical trials for medical products aiming at preventing or treating life-threatening diseases where there is no alternative therapy. In addition, this review can apply to products listed by WHO Emergency Use Assessment and Listing (EUAL) Procedure and African Vaccine Regulatory Forum (AVAREF) readiness plan.

The review of the application for compassionate use of unauthorized investigational products shall be based on the requirements set out in latest version of AVAREF Guidance and Considerations on Compassionate Use Access.

3.5 Review of additional data & updates on clinical Applications

The sponsor or principal investigator is responsible for preparing responses to queries raised by the Authority during the review process of CTAs or CTA-As. Any new information available for the investigational product such as adverse effects, updates to the Investigator Brochure, changes in formulation or manufacturer for the active ingredients or finished products shall be notified to the Authority.

Rwanda FDA reviews the query responses/clarifications provided and if the information is satisfactory, the CTAs or CTA-As approval process are initiated. If the applicant provides non - satisfactory query responses for two successive times for the same requested information, the application shall be rejected.

3.6 Review of quality, non-clinical and clinical data

The Authority reviews quality, non-clinical and clinical data submitted to support clinical trial application. Reviewers shall pay attention on potential safety issues which may influence eventual clinical application of the investigational products.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

3.6.1 Quality Review of investigational product (s)

The Authority reviews the quality part of the investigational products including placebo to ensure that the Chemistry, Manufacturing and Control (CMC) is consistently followed from active substance to finished products.

The reviewers shall verify the validity and authenticity of GMP certificate or confirmation of GMP compliance or GMP inspection report issued, by other regulatory authorities. In order to accept the GMP compliance, the Authority may rely on valid and authentic GMP certificate, confirmation or GMP inspection report issued by:

- a) Stringent Regulatory Authorities/WHO listed authorities;
- b) Competent Authority of countries that are standing PIC/s members;
- c) World Health Organization (WHO) prequalification program;
- d) Authorities operating at least at maturity level 3(ML3);
- e) Competent Authority that has a recognition agreement with the Authority;
- f) EAC Joint GMP inspection procedure.

In case the investigational product is manufactured in a country whose GMP control system is not recognized by the Authority, but the clinical trial has been authorized by one of the stated bodies a, b, c, d, e, and f, the decision from that body may be considered.

The information related to investigational product quality will be reviewed using a template as per **ANNEX-V** Template for Investigational Product Quality Review quality assessment template adopted from latest version of the AVAREF tools.

3.6.2 Review of non-clinical data

The review of non-clinical data will be performed focusing on the new information. A non-clinical overview on the pharmacology, pharmacokinetics, toxicology and other considerations such as Good Laboratory Practices.

The reviewer will ensure that non-clinical aspects of the SmPC are in line with the SmPC of the reference product. In addition, the reviewer (s) will provide the conclusion by using one of the following two options:

 a) Pharmacodynamic, pharmacokinetic and toxicological properties of investigational products <ACTIVE SUBSTANCE> are well known. As <ACTIVE SUBSTANCE> is a widely used, well-known active substance, the applicant has provided additional studies and further studies are not required. Overview based on literature review is, thus, appropriate.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

b) The reviewer(s) considers that the non-clinical overview on pre-clinical pharmacology, pharmacokinetics and toxicology is not adequate.

If the second option is chosen, the reviewer shall provide a detailed description of the missing information and its impact. This should then be translated into the draft list of questions.

The review of non-clinical data shall be made using the template for review of non-clinical data as per **ANNEX-VI** adopted from the latest version of the AVAREF tools.

3.6.3 Review of Clinical Data

During the review of clinical trial applications, the Authority shall raise any concerns about compliance with GCP or related regulatory and ethical requirements (data accuracy or protocol compliance and compliance with ethical aspects) using the template for review of clinical trial. The following will be taken into consideration where applicable:

- a) Product Development Rationale
- b) Overview of Biopharmaceutics (If applicable)
- c) Overview of Clinical Pharmacology
- d) Overview of Efficacy (If applicable)
- e) Overview of Safety
- f) Benefits and Risks Conclusions

3.7 Statistical Review of Clinical trial application

The Authority reviews the type of design (controlled, uncontrolled), randomization blinding, sample size determination, trial power and level of significance.

The primary and secondary variables ('target' variable, primary endpoint) will be reviewed to ensure that the proposed variable are capable of providing the most clinically relevant and convincing evidence directly related to the primary objective of the trial. The selection of the primary variable should reflect the accepted norms and standards in the relevant field of research

3.8 General review report for Clinical Trial Applications

The first and second reviewers of CTAs will generate a review report which shall include administrative and scientific details as well as other relevant information on the different sections of the protocol. In the event that there are no outstanding queries, the report will be presented and

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

discussed during the Clinical Trial Technical Committee (CTTC) to make a recommendation for final regulatory decision.

4.0. REVIEW OF AMENDMENTS AND RENEWAL OF CLINICAL TRIAL

The Authority shall review the substantial amendment and renewal applications for approval or rejection. In the event that these applications meet regulatory requirements, the Authority shall issue new certificates. The review shall depend on requirements for amendments or renewals as set out in the guidelines for Clinical Trial Applications in Rwanda.

The Authority shall review and approve any amendments before being implemented unless it is an urgent safety measure for trial participants. The urgent amendment shall be notified within 15 days for approval to the Authority thereafter. The list of amendments and necessary required documents prior to the approval of the amendment are detailed in the Guidelines on Clinical Trial Applications in Rwanda. The Authority will compare the new change to the previously submitted information in the protocol. The Authority reviews the amended part of the protocol and its supplementary document using the template for review of amendments as per **ANNEX-VII**.

The Authority shall review the renewal application against the requirements of renewal as stipulated in the guidelines of CTA, but also taking into account absence of harm to the trial participants in concordance with progress report and the approved protocol.

5.0. CLINICAL TRIAL APPROVAL PROCESS

Upon successful review and approval of a clinical trial application, the Authority issues a Clinical Trial Approval Certificate (CTAC) with specific number and conditions on the attachment as per the template of the CTAC is attached as **ANNEX-III.** The CTAC will have the following information: protocol title, protocol number and version if applicable, name (s) of investigational product (s) including placebo, name (s) of investigator(s), name (s) of sponsor (s), name (s) of trial sites, name of Contract Research Organization (CRO) if applicable, date of issuance and expiration date, name and signature of the Director General of the Authority.

For renewal, the Authority issues approval certificate of renewal with new validity and keep the reference number and name of the initial CTAC. In the case of amendment, the Authority shall keep the same CTAC and notify in writing the sponsor/PI.

When the sponsor/PI has not initiated the clinical trial after approval, he/she is required to communicate in writing within three (3) months. Failure to abide by the aforementioned compliance shall result to temporal CTAC suspension by the Authority until its expiration unless the sponsor/PI requests for reinstatement.

5.1 Clinical trial registration

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

The Authority will establish, maintain and publish of a register or database of approved, rejected clinical trial applications. The information required for register of clinical trials will include the following:

- a) Application reference number
- b) Protocol title
- c) Sponsor
- d) Principal investigator
- e) Investigational product (s) name and category
- f) Clinical trial site
- g) Clinical Trial Phase
- h) Targeted number of trial participant
- i) Clinical trial duration
- j) Status of the trial
- k) Certificate number and validity

5.2 Publication and maintenance of clinical trial register

The Authority ensures that the register has relevant information on approved, rejected and summary of evaluation report of clinical trial applications. The outcomes of completed trials, a list and respective reasons of suspended and/or terminated clinical trials will be published and updated on monthly basis.

6.0. POST TRIAL PROTOCOL REVIEW

The authority shall review the post-trial access protocol of completed clinical trials to ensure equitable access of the treatment for the safety and welfare of trial participants until the product is commercially available. Upon satisfactory information, the Authority shall issue a notification letter for Post-Trial Access. The decision to grant post-trial access will depend on the participant's medical need, including the availability of alternative therapies and review of what is known about the benefits and risks of the investigational product. The Authority may consider granting post-trial access even when the trial was discontinued or had negative outcomes, as long as the trial was not stopped for major safety issues. The criteria include but are not limited to the following:

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

- a) participant must have a serious or life-threatening condition
- b) the treating physician and/or investigator has determined that post-trial access is the best medical option for the patient;
- c) investigational product must not already be approved/authorized in that indication;
- d) the participant must have been a part of the trial in which the experimental product was administered;
- e) the administration of the product must have resulted in clinical benefit to the individual based on the investigator's assessment of the participant's response to the intervention and what is known about the risks of using the investigational product at the time of the decision;
- f) Sponsor must accept and have an adequate supply of experimental products.

ENDORSEMENT OF TE GUIDELINES

	Author	Authorized by	Checked by	Approved by
Title	DM/ Pharmacovigilance & Food Safety Monitoring	HoD/ Food & Drugs Inspections & Safety Monitoring	Quality Assurance Analyst	Director General
Names	NTIRENGANYA Lazare	Dr Eric NYIRIMIGABO	NDAYAMBAJE Théogène	Dr Emile BIENVENU
Signature	(N Eine?	Minty	Hermor	
Date	04/04/2023	04/04/2023	05/04/2023	05 / 04 / 2023


Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEXES

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Format: QMS/FMT/00 Revision No: 1 Effective Date: 20/06/2	Unit	Pharmacovigila Monitoring Div	2
Document Type: Pr	ocess Flow Chart	Doc. No	: FDISM/PVSM/CHT/002
All and a start of the start of		Revision Numbe	r : 01
	Clinical Application Review Process Review	Revision Date	: 03/04/2023
	I TOLESS NEVIEW	Effective Date	: 11/04/2023
RWANDA FDA		Review Due Dat	e : 10/04/2026
Rwanda Food and Drugs Authority		Ref Doc.	: FDISM/PVSM/GDL/008

ANNEX-I: CTA REVIEW PROCESS FLOW CHART



Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Format: QMS/FMT/00 Revision No: 1 Effective Date: 20/06/2	Unit	e/Pharmacovigila Monitoring Div	
Document Type: Cl	necklist	Doc. No	: FDISM/PVSM/CKL/008
ALL IN AND AND AND AND AND AND AND AND AND AN		Revision Numb	er : 01
	Title: Screening of clinical trial application	Revision Date	: 03/04/2023
	ti lai application	Effective Date	: 11/04/2023
RWANDA FDA		Review Due Da	te : 10/04/2026
Rwanda Food and Drugs Authority		Ref Doc.	: FDISM/PVSM/GDL/008

ANNEX-II: Screening checklist of clinical trial application

Date of the submission (cover letter)	
Date of receipt (Rwanda FDA stamp)	
Application Reference Number	NNNN/YYYY (e.g.: 00000/2023)
Date of Application Screening	
Type CT Application	□ New Application (CTA)
	□ Amendment Application (CTAA)
Title of Clinical Trial Application	
Protocol Reference Number	
Protocol Version Number (where applicable)	
Name and complete address of CTA Applicant	
Names of Principal Investigator	
Names of Co-Investigator	
Names of Sponsor (If applicable)	
Name and address of the Contract research	
Organisation (s) (CRO)where the clinical	
studies proving efficacy and safety of the	
product were conducted.	
Phase of Trial (if applicable)	
Number of Participants	
Number of Clinical Trial Site(s)	
List of Clinical Trial Sites	
Duration of Clinical Trial	
Name of Investigational Product (IP)	
Proprietary Product Name (if relevant)	
International Non-proprietary Name (INN) of	
the Active Ingredient (API), strength, dosage	
form.	
Name (s) and complete address (es) of the	
manufacturer (s) of the Investigational	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

product (s), inc	luding the final product release			
if different from	n the manufacturer.			
Investigational	Product Therapeutic			
Indications				
Investigational	Product Route of			
Administration				
	Product Storage Information			
Special Consid				
Conclusion of	the CTA Screening Report		nmended for Re	eview
		□ Recon	nmended for re	-submission
List of missin	g regulatory requirements if			
any				
Module I	Administrative Information Information	and P	rotocol Relat	ed
1.1	Screening of admini	strative	Tick as	Comment(s)
	Information		appropriate	
1.1.1	Signed and dated Clinica	l Trial	🗆 Yes	
	Application Cover letter		🗆 No	
1.1.2	Signed and dated clinical trial		🗆 Yes	
	application form-ANNEXURE-I		🗆 No	
1.1.3	Valid Ethical Clearance Certificate		🗆 Yes	
	from Rwanda National Ethics		□ No	
	Committee		_	
1.1.4	Curriculum vitae (CVs) of I	Principal	🗆 Yes	
	investigator and Co-investigator	or(s)	🗆 No	
1.1.5	Copy of Valid GCP Certific	ates for	🗆 Yes	
	both Principal Investigator	and co-	− □ No	
	Principal investigator (s)			
1.1.6	Signed and dated Joint dec	claration	🗆 Yes	
	between Sponsor & Principal		🗆 No	
	Investigator for sufficient funds in the			
	prescribed format (ANNEXURE-III)			
1.1.7	Signed and dated declarations by the		□ Yes	
	Principal investigator and/or Co-		□ No	
	investigators (ANNEXURE-V		.	
1.1.8	Valid Local Insurance Policy C	Covering		
	trial participants;		🗆 No	
1.1.9	Signed and dated Sponsor/ I	Principal	🗆 Yes	
	investigator contractual Agreer	nent;	□ No	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Review and Approval of Clinical Trials

1.1.10	Letters of Access authorizing Authority	🗆 Yes	
	to access related files (Drug Master	□ No	
	Files, Site Reference Files) must be		
	submitted;		
1.1.11	Clinical Trial Site Agreement/contract;	🗆 Yes	
		□ No	
1.1.12	Minutes of the discussions and	□ Yes	
	conclusions of the pre-submission		
	meeting or other relevant		
	correspondence with the Authority, if		
	applicable;		
1.1.13	List of Competent Authorities to which	🗆 Yes	
	the same application has been	□ No	
	submitted and details of decisions, if		
	available		
1.1.14	Evidence of payment of prescribed	□ Yes	
1.1.1.1	fees.		
1.0			
1.2	Clinical Trial Protocol-related Informa	ition	
1.2.1	A copy of the final proposed	🗆 Yes	
	protocol(s), including the version	□ No	
	number. The trial protocol must be		
	number. The trial protocol must be signed by the sponsor and the		
	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the		
	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2).		
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms	□ Yes	
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and		
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by	□ Yes	
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee	□ Yes	
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the	□ Yes	
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the	□ Yes	
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of	□ Yes	
	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial.	□ Yes □ No	
1.2.2	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. 1. Copy of Participant Information	□ Yes □ No	
1.2.3	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. 1. Copy of Participant Information Leaflet (PIL).	□ Yes □ No □ Yes □ No	
	 number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. Copy of Case Report Forms (CRFs) 	□ Yes □ No	
1.2.3	number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. 1. Copy of Participant Information Leaflet (PIL).	□ Yes □ No □ Yes □ No	
1.2.3	 number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. Copy of Case Report Forms (CRFs) 	□ Yes □ No □ Yes □ No □ Yes	
1.2.3	 number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. Copy of Case Report Forms (CRFs) to be used (hard copy or electronic) 	□ Yes □ No □ Yes □ No □ Yes □ No □ Yes	
1.2.3	 number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. Copy of Case Report Forms (CRFs) to be used (hard copy or electronic) Capacity building plan including 	□ Yes □ No □ Yes □ No □ Yes □ No	
1.2.3	 number. The trial protocol must be signed by the sponsor and the investigator prior to the start of the clinical trial (ICH E6 8.2.2). A copy of the Informed Consent Forms (ICFs) in English, French and Kinyarwanda signed and stamped by the Rwanda National Ethics Committee that includes a statement regarding the risks and anticipated benefits to the clinical trial participants as results of their participation in the clinical trial. Copy of Case Report Forms (CRFs) to be used (hard copy or electronic) Capacity building plan including training and updating of staff involved 	□ Yes □ No □ Yes □ No □ Yes □ No □ Yes	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

1.2.7 5. Signed Charter of DSMB and CVs of Members if applicable Yes of Members if applicable No 1.2.8 6. Signed and dated Materials Transfer Agreement (MTA) if applicable; Yes Dodule II Screening Information related to the Quality of Investigational Product (Chemistry, Manufacturing, and Control Summaries) 2.1 Investigational Product (IP) Dossier containing the Quality of Verall Summary and showing the chemistry, manufacture, and control (CMC) as proceed to the Quality of Investigational Product (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical, and available clinical data. Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report No 2.4 A copy of the identification labels for both primary ad secondary packaging (outer and inner packaging) of Investigational product labels Yes 2.5 Investigational product package Insert/s for mark No 2.6 Mock-up labels for the Investigational product labels No <th></th> <th></th> <th>🗆 No</th> <th></th>			🗆 No	
of Members if applicable □ No □ NA 1.2.8 6. Signed and dated Materials Transfer Agreement (MTA) if applicable; □ Yes □ NA □ No Modulc II Screening Information related to the Quality of Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. □ Yes 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical data. □ Yes 2.3 Copy of valid Good Manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report □ No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels □ Yes 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels □ No 2.5 Investigational product labels □ Yes 2.6 Mock-up labels for the Investigational □ Yes	1.2.7	5. Signed Charter of DSMB and CVs		
1.2.8 6. Signed and dated Materials Transfer Agreement (MTA) if applicable; □ NA Module II Screening Information related to the Quality of Investigational Product (Chemistry, Manufacturing, and Control Summaries) No 2.1 Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. □ Yes 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical, and available clinical data. □ Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report □ Yes 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inmer packaging) of Investigational product labels □ Yes 2.5 Investigational product labels □ Yes 2.6 Mock-up labels for the Investigational □ Yes		-	_	
1.2.8 6. Signed and dated Materials Transfer Agreement (MTA) if applicable; □ Yes □ No 1.2.8 6. Signed and dated Materials Transfer Agreement (MTA) if applicable; □ No □ No 1.2.8 Screening Information related to the Quality of Investigational Product (Chemistry, Manufacturing, and Control Summaries) No □ NA 2.1 Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. □ Na 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, nonclinical data. □ Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report □ No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels □ No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging		11		
Agreement (MTA) if applicable; Investigational Product (Chemistry, Manufacturing, and Control Summaries) 2.1 Investigational Product (IP) Dossier Yes containing the Quality Overall No No Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. INO 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical, and available clinical data. INO 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report No 2.4 A copy of the identification labels for both primary and secondary packaging of Investigational product labels INO 2.5 Investigational product labels INO 2.6 Mock-up labels for the Investigational INO	1.0.0			
Module II Screening Information related to the Quality of Investigational Product (Chemistry, Manufacturing, and Control Summaries) 2.1 Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Image: No Stream of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: No Stream of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: No Stream of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: No Stream of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: No Stream of the safety, non- clinical, and available clinical data. 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Image: No 2.4 A copy of the identification labels for Investigational product labels Image: Yes Image: No 2.5 Investigational product package Insert/s for mark Image: Yes	1.2.8	e		
Module II Screening Information related to the Quality of Investigational Product (Chemistry, Manufacturing, and Control Summaries) 2.1 Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Image: No 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: No 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Image: Yes Image: No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Image: Yes Image: No 2.5 Investigational product package Insert's for mark Image: Yes Image: No		Agreement (MTA) if applicable;	□ No	
(Chemistry, Manufacturing, and Control Summarics) 2.1 Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. NA 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical, and available clinical data. Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Yes 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Yes 2.5 Investigational product package Insert's for mark Yes				
2.1 Investigational Product (IP) Dossier containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. NA 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical, and available clinical data. Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Yes 2.5 Investigational product package Insert's for mark No 2.6 Mock-up labels for the Investigational Yes	Module II	Screening Information related to the Q	Quality of Inve	estigational Product
containing the Quality Overall Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. NA 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. No 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Yes 2.5 Investigational product package Insert/s for mark No 2.6 Mock-up labels for the Investigational Yes		(Chemistry, Manufacturing, and Control S	Summaries)	-
Summary and showing the chemistry, manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. NA 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Yes 2.5 Investigational product package Insert/s for mark Yes	2.1	e v	🗆 Yes	
manufacture, and control (CMC) as per Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Image: State Stat			🗆 No	
Common technical document (CTD) format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Image: Common technical data 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: No 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Image: Yes Image: No 2.5 Investigational product package Insert/s for mark Image: Yes Image: No				
format in Annexure-IV, non-clinical data, and Data from previous clinical use (if applicable). In the case of First-in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non-clinical, and available clinical data. 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels 2.5 Investigational product package Insert/s for mark 2.6 Mock-up labels for the Investigational				
data, and Data from previous clinical use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Yes Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) (outer and inner package Insert/s for mark No Yes				
use (if applicable). In the case of First- in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Image: State Stat				
in-human (FIH) studies, toxicity and PK/PD reports should be included in the dossier. Image: Secondary should be included in the dossier. 2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. Image: Secondary should be included in the aution of the salid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Image: Secondary packaging (outer and inner packaging) of Investigational product labels 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Image: Secondary package Insert/s for mark Image: Secondary package Image: Secondary package Image: Secondary package Image: Secondary package 2.6 Mock-up labels for the Investigational Image: Secondary package				
PK/PD reports should be included in the dossier. Image: state of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, nonclinical, and available clinical data. Image: state of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, nonclinical, and available clinical data. Image: state of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, nonclinical, and available clinical data. Image: state of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, nonclinical, and available clinical data. Image: state of the current Investigation Isper Solution Isper Solutisper Solution Isper Solution Isper Solution				
the dossier. Image: spectral				
2.2 A copy of the current Investigator's Brochure (IB), supplemented as appropriate with up-to-date safety, non- clinical, and available clinical data. □ Yes 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report □ Yes 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels □ Yes 2.5 Investigational product package Insert/s for mark □ Yes		-		
Brochure (IB), supplemented as appropriate with up-to-date safety, nonclinical, and available clinical data. Image: No 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Image: No 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Image: Yes 2.5 Investigational product package Insert/s for mark Image: Yes 2.6 Mock-up labels for the Investigational Image: Yes	2.2			
appropriate with up-to-date safety, non- clinical, and available clinical data. Image: Non- clinical, and available clinical data. 2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Image: Non- inspection report 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Image: Non- inspection report 2.5 Investigational product package Insert/s for mark Image: Non- inspection report 2.6 Mock-up labels for the Investigational Image: Yes	2.2			
clinical, and available clinical data.2.3Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection reportI Yes2.4A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labelsI Yes2.5Investigational product package Insert's for markI Yes2.6Mock-up labels for the Investigational I I Yes				
2.3 Copy of valid Good Manufacturing Practice (GMP) Certificate or ISO Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report □ Yes 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels □ Yes 2.5 Investigational product package Insert/s for mark □ Yes 2.6 Mock-up labels for the Investigational □ Yes				
Practice (GMP) Certificate or ISO Imanufacturing Certificate OR Copy of the valid Imanufacturing imanufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report Image: Secondary packaging (outer and inner packaging) Image: Secondary package (outer and inner packaging) Image: Secondary package Investigational product labels Image: Secondary package 2.5 Investigational product package Insert/s for mark Image: No 2.6 Mock-up labels for the Investigational	2.3		□ Yes	
Certificate OR Copy of the valid manufacturing license for all production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels □ Yes 2.5 Investigational product package Insert/s for mark □ Yes 2.6 Mock-up labels for the Investigational □ Yes			□ No	
production steps (not older than 3 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection reportYes2.4A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labelsNo2.5Investigational product package Insert/s for markYes2.6Mock-up labels for the InvestigationalYes				
 years) OR Confirmation document of the authority that the manufacturer complies with PIC/S OR GMP inspection report A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels Investigational product package Insert/s for mark Mother Mock-up labels for the Investigational 		manufacturing license for all		
the authority that the manufacturer complies with PIC/S OR GMP inspection reportImage: Secondary packaging inspection report2.4A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labelsImage: Secondary packaging image: Secondary packa		production steps (not older than 3		
complies with PIC/S OR GMP inspection reportImage: Secondary packaging ispection report2.4A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labelsImage: Yes Image: Secondary package Image: No2.5Investigational product package Insert/s for markImage: Yes Image: No2.6Mock-up labels for the Investigational Image: Image: Image: No		•		
inspection report Image: spectral spectra spectral spectral spectral spectral spect		-		
 2.4 A copy of the identification labels for both primary and secondary packaging (outer and inner packaging) of Investigational product labels 2.5 Investigational product package Insert/s for mark 2.6 Mock-up labels for the Investigational □ Yes 		-		
both primary and secondary packaging (outer and inner packaging) of Investigational product labels Image: No 2.5 Investigational product package Insert/s for mark Yes 2.6 Mock-up labels for the Investigational Insert/s Yes				
(outer and inner packaging) of Investigational product labels Investigational product package Insert/s for mark 2.6 Mock-up labels for the Investigational	2.4			
Investigational product labels Investigational product package Yes 2.5 Investigational product package No 2.6 Mock-up labels for the Investigational Yes			D No	
 2.5 Investigational product package □ Yes Insert/s for mark □ No 2.6 Mock-up labels for the Investigational □ Yes 				
Insert/s for mark Image: No 2.6 Mock-up labels for the Investigational Yes	2.5			
2.6 Mock-up labels for the Investigational □ Yes	2.5		_	
			_	
$-\mathbf{N}_{-}$	2.6		🗆 Yes	
		product(s).	🗆 No	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Review and Approval of Clinical Trials

	Names	Date	Signature	
Clinical Trial	Screening Report Approvals			
Passed 🗆	Passed with addition requir	Passed with addition requirements		
	.5%), Insurance Cover (5%) and RNEC et		<i>2(2.5%).</i> Rejected □	
applicable fees (5%), declaration forms(2.5%), agreement between the sponsor and principal				
	s per prescribed format (40%), updated			
	the signed, dated application letter and for			
NOTE: The Clinical Trial Application pass the screening stage and accepted for review if the applicable required documents are provided, which will be scored out of 70% accordingly. This				
Overall outcom	me, comment and conclusion on Clinical	Trial applicat	tion	
		□ No		
3.2	Literature References	🗆 Yes		
	information such as publications			
3.1	Additional supporting quality	□ Yes		
	Other Supporting Information			
Module III				
	imported directly to the trial site			
2.10	case the investigational product is not			
2.10	Copy of the import authorization in	□ Yes		
	specifications, batches, stability and facility information			
	and quantitative list of ingredients,			
	manufacturing process, a qualitative			
	required including a description of the			
	information on the placebo is also			
2.9	Composition of the placebo if applicable (placebo-controlled trials,			
2.9	to be used in a clinical trial if applicable Composition of the placebo if	- Vac		
	batches of the investigational products	D No		
2.8	Copy of Certificate of analysis for the	🗆 Yes		
	(COPP) of the investigational products			
	certificate of pharmaceutical product			
2.7	characteristics (SmPC) or a copy of the			
2.7	Copy of the summary of product	🗆 Yes		

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-III: Template for review of clinical trial application



Rwanda Food and Drugs Authority Nyarutarama Plaza, KG 9 Avenue P.O. Box: 1948 Kigali - Rwanda Email: <u>info@rwandafda.gov.rw</u> website: <u>www.rwandafda.gov.rw</u>

QMS N°: FDISM/PVSM/FMT/003 Revision No: 01 Effective Date: 11/04/2023

Review of Clinical Trial Application

Date of the submission (cover letter)			
Date of receipt (Rwanda FDA stamp)			
Application Reference Number	NNNN/YYYY (eg. 00000/2023)		
Reviewers and Review Date			
First Reviewer	Name	Date	Signature
Second Reviewer			
Type CT Application	New Applicati	$\frac{1}{0}$ on (CTA)	
Type CT Application	Amendment A	· · · ·	TAA)
Title of Clinical Trial Application		ppneution (e	
Protocol Reference Number			
Protocol Version Number (if applicable)			
Name and complete address of CTA			
Applicant			
Names of Principal Investigator			
Names of Co-Investigator			
Names of Sponsor and address			
(If applicable)			
Name and address of the Contract research			
Organization (s) (CRO) where the clinical			
studies proving efficacy and safety of the			
product were conducted.			
Phase of the Trial (if applicable)			
Number of Participants			
Number of Clinical Trial Site(s)			
List of Clinical Trial Sites			
Duration of Clinical Trial			
Name of Investigational Product (IP)			
Proprietary Product Name (if relevant)			
International Non-proprietary Name (INN)			
of the Active Ingredient (API), strength,			
dosage form.			

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Name (s) and complete address (es) of the	
manufacturer (s) of the Investigational	
product (s), including the final product	
release if different from the manufacturer.	
Investigational Product Therapeutic	
Indications	
Investigational Product Route of	
Administration	
Investigational Product storage Information	
Special Storage consideration	
Overall Conclusion of the CTA Review	
	ADDITIONAL DATA REQUESTED
	REJECTED
Points to be communicated with the	
Clinical Trial Applicant:	
Please copy all relevant information to be	
communicated to the CT applicant in the	
corresponding letter and save it accordingly	
Clinical Trial Commitments (if any)	
General remarks to next assessors:	
List issues identified during the assessment	
for the follow up assessment, such as	
information to be confirmed, to be verified,	
etc.	
Recommendations to GCP Inspectors:	
-	
List issues identified during the CT	
assessment phase that require verification	
during a GCP inspection	
Recommendations to GCP Inspectors	
SCIENTIFIC REVIEW	
1 Background Information	

(Insert a brief, concise introduction into the clinical problem and previous treatments and developments, i.e., pertinent data from previous preclinical/clinical pharmacology studies and therapeutic exploratory studies taking into account relevant scientific literature (citations by consecutive numbering, with list at end of this section; important or not readily available references may be included with the paper submission, if appropriate). This section should also contain information on the new drug). Provide rationale for conducting the study in Rwanda

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

1.1 Low intervention trial

Based on the background information provided, is the trial a low-risk intervention? **YES NO**

Low-intervention clinical trial means a clinical trial which fulfills all of the following conditions: (a) the investigational medical products, excluding placebos, are authorized; (b) according to the protocol of the clinical trial, (i) the investigational medical products are used in accordance with the terms of the marketing authorisation; or (ii) the use of the investigational medical products is evidence-based and supported by published scientific evidence on the safety and efficacy of those investigational medical products in other countries; and (c) the additional diagnostic or monitoring procedures do not pose more than minimal additional risk or burden to the safety of the participants compared to normal clinical practice. Source: Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use.

If YES , is the justification provided for the clinical trial intervention as provided by the sponsor is acceptable ? \Box YES

If No - tick appropriate box below and comment

The investigational medical products used in the study, excluding placebos, are not authorized **YES**

The investigational medical products are not used in accordance with the terms of the marketing authorization and the use of the investigational medicinal products is not evidence-based \Box YES

The additional diagnostic or monitoring procedures pose more than minimal additional risk or burden to the safety of the participants compared to normal clinical practice **YES**

Reviewer's comments:

1.1.2 The phase of the trial (skip if a low intervention):

1.1. 2.1 The phase of the trial (*skip if a low intervention*):

Reviewer's comments:

1.1.2.2 Therapeutic condition (Brief description of the disease):

Reviewer's comments:

1.1.2.2 Mechanism of action, drug class (*Add a brief description***):**

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Reviewer's comments:

1.1.2.3. Status of development: (Brief discussion of clinical pharmacokinetic data, efficacy and safety data described in the IB from previous trials /previously investigated indications(s) for the IMP(s). Non-clinical studies may also be discussed for early or FIH clinical trials. Consideration should be given to the justification provided based on the non-clinical data, for the proposed starting dose, dose steps, and maximum exposure)

Reviewer's comments:

1.2 CLINICAL TRIAL RATIONALE: (*Consider what is new in this trial, the clinical relevance, and the medical need that the trial aims to address:*

Reviewer's comments:

2. Review of objective and endpoints of the trial

(Insert the objectives that are the same as the objectives contained in the protocol. Include the primary objective and secondary objectives) **Primary Objective(s):**

Secondary Objective(s):

Reviewer's comments:

3. **Review of Endpoints**

(Insert the endpoints that are the same as the endpoints contained in the body of the protocol. Include the primary endpoint and important secondary endpoints) **Primary Endpoint(s):**

Secondary Endpoint(s):

Reviewer's comments:

4. Review of Design

4.1. Insert summary description of the type/design of trial to be conducted (e.g. double-blind,

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

placebo-controlled, parallel design). Provide a simple summarized snapshot of your study design not to exceed a single page. This section should include a diagram that provides a quick to 1 page. Please present an overview of your study design in a schematic diagram and tables. The data presentation can be adapted depending on the nature of your study and can be customized according to your protocol.

Example: complete the tables with study-specific information and adapt the table(s) to illustrate your study design.

Arm 1	Sample size	Intervention A
Arm 2	Sample size	Intervention B

Include instructions for progressing to next phase (if applicable):

Include a schematic diagram to show the design, procedures and stages including study arms, visits, time-points, interventions etc.

4.2. Summary of the randomization method and procedures to allocate participants to treatment groups;

4.3. Blinding (methods of blinding (masking) and other bias reducing techniques to be used);

4.4. Summary description of the trial treatment(s) and the dosage and dosage regimen of the investigational product(s), including packaging, and labelling of the investigational product(s);

4.5. *Maintenance of trial treatment randomization codes and procedures for breaking codes;*4.6. *Total study duration (anticipated starting/ finishing dates);*

4.0. Total study duration (anticipated starting/ jinishing dates),

4.7. *Expected duration for each subject including post-treatment period etc;*

Reviewer's comments:

If YES, specify which population(s):

Is the inclusion of the vulnerable population is justifiable and the benefit/risk profile is acceptable \Box **YES** \Box **NO**

If the trial is for emergency clinical trials, Does the trial provide clinically relevant direct benefit to the participants?

YES NO NA

Reviewer's comments:

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

5.5. Provide a brief description of specific characteristics of the trial participants (e.g. disease/ stage/ indication/ conditions/ treatment etc.) as applicable and of diagnostic criteria and assessment:

Reviewer's comments:

5.6. *State the Inclusion criteria:*

5.7. *State the Exclusion criteria:*

Reviewer's comments:

6. Premature Withdrawal / Discontinuation Criteria

6.1. Withdrawal criteria:

6.1.1. Enumeration of all conditions/criteria and management for drug/ patient's withdrawal or (premature) discontinuation, including voluntary withdrawal by subject without prejudice to future treatment by the physician. The type and timing of the data to be collected for withdrawn participants.

6.1.2. *State whether and how participants are to be replaced.*

6.1.3. *The follow-up for participants withdrawn from investigational product treatment/trial Treatment*

6.2. State the stopping rules" or "discontinuation criteria" for individual participants, parts of trial and entire trial;

Reviewer's comments:

7. Review of Quality of the Investigational Products and its Formulation

7.1. (Brief description of the study drug(s) and formulation to be used in the clinical trial. The relationship to the formulations used in the preclinical and/or other clinical trials should be delineated, as applicable. This may also include disclosure of the formulation intended to be marketed and/or any bridging studies which may be necessary, planned, initiated and/or already performed if different formulations have been used during clinical development.)

7.2. *Instructions for safe handling;*

7.3. *State the accountability procedures for the investigational product(s), placebos and comparator(s) and disposal;*

7.4. State information related to the available safety data and risk benefits assessment

7.5. In the case of phase I, II, and III review the investigational product dossier and assess data including the non-clinical data. For marketed product review the SmPC of the investigational products

Reviewer's comments:

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

8. Review of Investigational products and Dosage Regimen

- **8.1.** *Rationale for dose selection*
- **8.2.** *Provide the following regarding the treatment(s) to be administered:*
- **8.3.** *The name(s) of all the product(s):*
- **8.4.** *Dose(s):*
- **8.5.** *The dosing schedule(s):*
- **8.6.** *The route/mode(s) of administration:*
- **8.7.** *The treatment period(s):*
- **8.8.** Follow-up period(s) for participants for each investigational product treatment/trial treatment group/arm of the trial:

8.8.1. Concomitant Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or during the trial:

8.8.2. *Procedures for monitoring participant's compliance:*

8.8.3. *Wash-out period (Description for pre-, during- and post-trial, as applicable)*

8.8.4. *The trial includes the investigation of a medical device(s) that is considered acceptable:*

Reviewer's comments:

The trial includes the investigation of a medical device(s) that is considered acceptable:

9. Review of Pre-study Screening and Baseline Evaluation

(Describe in summary the process of clinical validation for participation in the clinical trial, including methodology / schedule of events.

Reviewer's comments:

10. Review of Treatment / Assessment Visits

(Insert the schedule of all events / visits / procedures during the clinical trial) Reviewer's comments:

11. Review of Efficacy Variables and Analysis

11.1. Description and validation of primary endpoint(s), i.e. responses/changes from baseline over time in relation to clinical trial events. Description and validation of related secondary changes (secondary endpoints) following from clinical trial events.

11.2. *Provide specification of the efficacy parameters.*

11.3. *Describe the methods and timing for assessing, recording, and analyzing efficacy parameters*

Reviewer's comments:

12. Review of Safety

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

12.1. Specification of safety parameters:

12.2. The methods and timing for assessing, recording, and analyzing safety parameters:

12.3. *Procedures for eliciting reports of and for recording and reporting adverse events and intercurrent illnesses.*

12.4. The type and duration of the follow-up of subjects after adverse events

12.5. Summarize the information related to experience of the investigator (s: Curriculum vitae (CVs) of Principal investigator and Co-investigator(s) and GCP certificates to ensure the training, experience and qualification to supervise the implementation of the trial:

12.6. *RISKS: (Identify potential risks and mitigation strategies (e.g. need for and risks associated with long)*

12.7. *term immunosuppression)*

12.8. *DATA and SAFETY MONITORING PLAN (DSMP):*

(Summarize the Data and Safety Monitoring Plan. Describe measures that will be implemented to minimize risk to study subjects e.g. specific inclusions/exclusions; plans to ensure medical intervention in the case of an adverse event for subjects; plans for surveillance, detection and management of specific adverse events that might or could occur; potential use of an Independent Safety Monitor or Data Safety Monitoring Board (DSMB)

12.9. *Immune Monitoring and immunosuppression: (Describe and justify the plan for immunosuppression and immune monitoring (if applicable)*

Reviewer's comments:

13. Review of Assays/methodologies

13.1. Briefly describe any specialized assays or methodologies that will be used in this clinical study or supporting study/studies (Provide a more detailed summary of assay methods and summarize assay qualification/validation. Indicate where specialized testing will be conducted):

13.2. The names and contact addresses of the laboratories to be used for the study;

13.3. State the location of the attached draft Material Transfer Agreements (MTAs) in the submission;

13.4. State the duration for long term storage of samples and the area to be stored

Assessor's comments:

14. Review Statistical analysis plan

14.1. Specify the planned sample size to be used in the study and its justification

Planned number of participants to be enrolled:

Are the sample size calculation and justification acceptable? YES NO Are the trial power and level of significance acceptable? YES NO

Assessor's comments:

14.2. Summary of description of the statistical methodologies to be used to evaluate the effectiveness of the investigational product, including the hypotheses to be tested, the parameters to be estimated, the assumptions to be made and the level of significance and the statistical model to be used.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

14.3. Analysis of trial parameters (primary/ secondary endpoints), population, demographics, as applicable.

14.4. *Efficacy analysis methods and results of efficacy end-point analysis.*

14.5. Safety analysis methods and results of safety end-point analysis.

14.6. Exploratory end-point analysis: evaluation effect(s) (or lack of effects) of relevant

biochemical/ pharmacological etc parameters, as applicable.

14.7. *Pharmacokinetic endpoint analysis, as applicable.*

14.8. Interim analysis and role of Data Safety Monitoring Board, as applicable

Reviewer's comments:

15. Outcome criteria

(Describe criteria that would define whether you would or would not move forward with the subsequent development plan, based upon primary and designated secondary objectives)

Reviewer's comments:

16. Review of Data management

(Describe procedures for recording, processing, handling, and retaining raw data and other study documentation)

Reviewer's comments:

17. Review of Monitoring plan

(Summary of the monitoring plan)

State the location of the detailed monitoring plan in the submission

Reviewer's comments:

18. Ethical considerations

18.1. State the ethical clearance reference number and institutions that have approved the trial Rwanda National Research Ethics Committee ethical clearance: RNEC ethical clearance number and Date:

18.2. *Insurance Details :*

18.2.1. Insert local Insurance Company name and address:

18.2.2. policy cover number:

18.2.3. Validity:

18.2.4. *Expiry Date:*

18.2.5. *State the location of the Insurance cover in the submission:*

18.2.6. *List of Covered risks:*

18.3. *Participant Information sheets and Informed Consent forms: The contents should be as per ICH GCP guidelines, these guidelines and declaration of Helsinki)*

18.3.1. State the version number and dates for both English and Kinyarwanda versions

18.3.2. State the location of the Participant Information sheets and Informed Consent forms in the submission

18.4. *State the amount to be reimbursed to the participants:*

18.5. *Treatment and/or management of participants and their disease condition(s) after completion of trial*

18.6. Follow-up of trial study participants after the conclusion of the trial

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

18.7.	In case of transfer of materials, provide Material Transfer Agreement	(MTA)
highlig	ghting among other things, the following:	
18.8.	Identification of the provider and recipient	
18.9.	Identification of the material and the volume of material	

18.10. Definition of the trial and how the material will and will not be used.

18.11. Maintenance of confidentiality of background or supporting data or information, if any

18.12. Indemnification and warranties (where applicable)

18.13. *Details on post-trial access to the products*

Assessor's comments:

19. Benefit/risk assessment

The protocol contains an acceptable evaluation of the anticipated benefits and risks of participating
in the trial YES NO
Are the measures proposed to address the known and potential risks of participating in the trial and
to protect participants acceptable? VES NO

Reviewer's comments:

Based on medical and ethical principles the anticipated benefits to the participants or to public health do not justify the foreseeable risks and inconveniences, or compliance with this condition is not constantly monitored Rights of the participants to physical and mental integrity, and privacy are insufficiently safeguarded in the study The clinical trial has not been designed to involve as little pain, discomfort, fear and any other foreseeable risk as possible, or both the risk threshold and the degree of distress are not defined in the protocol or are not monitored

GENERAL COMMENTS ON THE REVIEW

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-IV: Template of clinical trial approval certificate

RWANDA FDA Rwanda Food and Drugs Authority	Nyarutarama Plaza, KG 9 A P.O. Box: 1948 Kigali - Rw Email: <u>info@rwandafda.go</u> website: <u>www.rwandafda.g</u>	anda V. <u>rw</u>	QMS N°: FDISM/PVSM/FMT/001 Revision No: 1 Effective Date: 11/04/2023
	CLINICAL TRIAL APPRO	OVAL CERT	<u>TFICATE</u>
	No. 003/2018 of 09/02/2018 estantion, and functioning in its articl		wanda FDA and determining its oh 7 and article 9, paragraph 2)
Clinical Trial Appr	oval Certificate Nº: [000/CTA/(0000-YYYY/	FDA/0000-YYYY]
This is to certify that conditions indicated	the clinical trial described below in this certificate.	has been app	proved in Rwanda subject to the
Protocol Title:			
Protocol Number a	nd version:		
Name of the Investi	gational product (s):		
	gational product (s): roduct(s)/Intervention (s)	Comparate	or (s)
Investigational P	oduct(s)/Intervention (s)		or (s)
Investigational P	roduct(s)/Intervention (s)	-	. ,
Investigational Pr	oduct(s)/Intervention (s)	-	·····
Investigational Pi Clinical Trial site (s Name of the Princip CRO/Research Inst	oduct(s)/Intervention (s)): pal Investigator(s):	-	·····
Investigational Pr Clinical Trial site (s Name of the Princip CRO/Research Inst Sponsor's name:	oduct(s)/Intervention (s)): pal Investigator(s):		·····
Investigational Pr Clinical Trial site (s Name of the Princip CRO/Research Inst Sponsor's name:	oduct(s)/Intervention (s)):)al Investigator(s): itution (s): 		·····
Investigational Pr Clinical Trial site (s Name of the Princip CRO/Research Inst Sponsor's name: Validity from: [DD	oduct(s)/Intervention (s)): 		·····

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Key Conditions for compliance

- 1. To notify Rwanda FDA about trial initiation within three (3) months;
- 2. To provide sufficient information to participants before recruitment;
- 3. To obtain informed consent from the participant prior to enrolment;
- 4. To comply with eligibility criteria while recruiting participants as per the approved trial protocol;
- 5. To seek approval of all substantial amendments related to the trial or trial protocol prior to the implementation;
- To notify Rwanda FDA of any Serious Adverse Events (SAEs) as soon as possible but not later than seven (7) calendar days using ADR/AEFI reporting form and submit a complete report within eight (8) next calendar days;
- To submit the progress and final report of the clinical trial to Rwanda FDA at the prescribed timelines;
- 8. To apply for renewal of Clinical Trial Approval Certificate one month before its expiration.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Review and Approval of Clinical Trials

ANNEX-V: Template of clinical trial approval certificate for renewal

RWANDA FDA Rwanda Food and Drugs Authority	Nyarutarama Plaza, KG 9 J P.O. Box: 1948 Kigali - Ry Email: <u>info@rwandafda.go</u> website: <u>www.rwandafda.g</u>	vanda v.rw	QMS Nº: FDISM/PVSM/FMT/036 Revision No: 0 Effective Date: 11/04/2023
	CLINICAL TRIAL APPR		
			wanda FDA and determining its h 7 and article 9, paragraph 2)
•	YYYY] of the clinical trial des	•	00/CTA/0000-YYYY/FDA/0000 has been renewed subject to the
Protocol Title:			
Protocol Number an	d version:		
Name of the Investig		6	
Investigational Pr	oduct(s)/Intervention (s)	Comparate	or (s)
Name of the Princip	: al Investigator(s): tution (s):		
Sponsor's name:		YY]	
Sponsor's name:	MM/YYYY] to [DD/MM/YY	YY]	
Sponsor's name: Validity from: [DD/	MM/YYYY] to [DD/MM/YY [DD/MM/YYYY]	YY]	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Key Conditions for compliance

- 1. To notify Rwanda FDA about trial initiation within three (3) months;
- 2. To provide sufficient information to participants before recruitment;
- 3. To obtain informed consent from the participant prior to enrolment;
- 4. To comply with eligibility criteria while recruiting participants as per the approved trial protocol;
- 5. To seek approval of all substantial amendments related to the trial or trial protocol prior to the implementation;
- To notify Rwanda FDA of any Serious Adverse Events (SAEs) as soon as possible but not later than seven (7) calendar days using ADR/AEFI reporting form and submit a complete report within eight (8) next calendar days;
- To submit the progress and final report of the clinical trial to Rwanda FDA at the prescribed timelines;
- 8. To apply for renewal of Clinical Trial Approval Certificate one month before its expiration.

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-VI: Template of additional data or query response



Rwanda Food and Drugs Authority

Nyarutarama Plaza, KG 9 Avenue P.O. Box: 1948 Kigali - Rwanda Email: <u>info@rwandafda.gov.rw</u> website: <u>www.rwandafda.gov.rw</u> QMS N°: FDISM/PVSM/FMT/004 Revision No: 01 Effective Date: 11/04/2023

Template of additional data or query response

Date of the submission (cover letter)			
Date of receipt (Rwanda FDA stamp)			
Application Reference Number	NNNN/YYY	YY (eg. 00000/2023)	
Reviewers and Review Date			
First Reviewer	Name	Date	Signature
Second Reviewer			
Type CT Application	□ New Appl	ication (CTA)	
		ent Application (CTAA	A)
Title of Clinical Trial Application			
Protocol Reference Number			
Protocol Version Number (if applicable)			
Name and complete address of CTA Applicant			
Names of Principal Investigator			
Names of Co-Investigator			
Names of Sponsor and address (If applicable)			
Name and address of the Contract research Organization (s) (CRO) where the clinical studies proving efficacy and safety of the product were conducted.			
Phase of the Trial (if applicable)			
Number of Participants			
Number of Clinical Trial Site(s)			
Duration of Clinical Trial			

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Name of Investigational Product (IP)	
Proprietary Product Name (if relevant)	
International Non-proprietary Name (INN)	
of the Active Pharmaceutical Ingredient	
(API), strength, pharmaceutical form.	
Name (s) and complete address (es) of the	
manufacturer (s) of the Investigational	
product (s), including the final product	
release if different from the manufacturer.	
Name (s) and complete address (es) of the	
manufacturer (s) of the Investigational	
product (s), including the final product	
release if different from the manufacturer.	
Investigational Product Therapeutic	
Indications	
Investigational Product Route of	
Administration	
Investigational Product storage Information	
Special Storage consideration	
Overall Conclusion of the CTA Review	□ ACCEPTED
	□ ADDITIONAL DATA REQUESTED
	□ REJECTED
Points to be communicated with the	
Clinical Trial Applicant:	
Clinical Trial Applicant : <i>Please copy all relevant information to be</i>	
Clinical Trial Applicant : Please copy all relevant information to be communicated to the CT applicant in the	
Clinical Trial Applicant : <i>Please copy all relevant information to be</i> <i>communicated to the CT applicant in the</i> <i>corresponding letter and save it accordingly</i>	
Clinical Trial Applicant : Please copy all relevant information to be communicated to the CT applicant in the	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any)	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors:	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified,	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc.	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors:	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspection	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspectors:	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspectors: List issues identified during the CT	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspection Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspectors: List issues identified during the CT	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) General remarks to next assessors: List issues identified during the assessment for the follow up assessment, such as information to be confirmed, to be verified, etc. Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification during a GCP inspection Recommendations to GCP Inspectors: List issues identified during the CT assessment phase that require verification	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Response from CT Applicant (1)
r r · · · ()
Comment from CT Assessor (1)
Question from Previous CT Assessor (2)
Response from CT Applicant (2)
Acsponse from C1 Applicant (=)
Comment from CT Assessor (2)
Oursetion from Dustions (T Assessor (2)
Question from Previous CT Assessor (3)
Response from CT Applicant (3)
Response from CT Applicant (5)
Comment from CT Assessor (3)
Question from Previous CT Assessor (4)
Response from CT Applicant (4)
Comment from CT Assessor (4)
Question from Previous CT Assessor (5)
Response from CT Applicant (5)

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Comment from CT Assessor (5)

ANNEX-VII: Template for Investigational Product Quality Review



Rwanda Food and Drugs Authority

Nyarutarama Plaza, KG 9 Avenue P.O. Box: 1948 Kigali - Rwanda Email: <u>info@rwandafda.gov.rw</u> website: <u>www.rwandafda.gov.rw</u> QMS N°: FDISM/PVSM/FMT/005 Revision No: 01 Effective Date: 11/04/2023

Investigational Product Quality Review

Date of the submission (cover letter)			
Date of receipt (Rwanda FDA stamp)			
Application Reference Number	NNNN/YYYY	(eg. 0000	0/2023)
Reviewers and Review Date			
First Reviewer	Name	Date	Signature
	-		
Second Reviewer			
Type CT Application	🗌 New Applic	ation (CT	A)
	Amendmen	t Applicat	ion (CTAA)
Title of Clinical Trial Application			
Protocol Reference Number			
Protocol Version Number (if applicable)			
Name and complete address of CTA Applicant			
Names of Principal Investigator			
Names of Co-Investigator			
Names of Sponsor and address			
(If applicable)			
Name and address of the Contract research			
Organization (s) (CRO) where the clinical studies			
proving efficacy and safety of the product were			
conducted.			
Phase of the Trial (if applicable)			
Number of Participants			
Number of Clinical Trial Site(s)			
Duration of Clinical Trial			
Name of Investigational Product (IP)			
Proprietary Product Name (if relevant)			

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	onal Non-proprietary Name (INN) of the harmaceutical Ingredient (API), strength,			
	eutical form.			
	and complete address (es) of the			
	urer (s) of the Investigational product			
	ding the final product release if different			
	manufacturer.			
	and complete address (es) of the			
	urer (s) of the Investigational product			
	ding the final product release if different			
	manufacturer.			
	tional Product Therapeutic Indications			
	tional Product Route of Administration			
	tional Product storage Information			
	torage consideration			
	Conclusion of the CTA Review	ACCEPTED		
		ADDITIONAL DAT	A REOUEST	ED
		REJECTED	X 0227	
Doints to	be communicated with the Clinical			
Trial Ap	-			
	ppy all relevant information to be			
	cated to the CT applicant in the			
	nding letter and save it accordingly			
Clinical 7	Trial Commitments (if any)			
REVIEV	V OF QUALITY OF INVESTIGATIO	NAL PRODUCT		
1	GMP Compliance			
	Valid Manufacturing License issued by	the competent Authority in	the country of	YES 🗌
	origin			NO
	Valid Good Manufacturing License Issu	ed by the competent Author	rity in the	YES 🗌
	country of origin			NO
	Registered, non-modified product only S	SmPC has been provided		YES
				NO
	Does the Drug substance have a monog	raph?		
		we do not not due to the	41	NO
	Does the active substance belong to an EU/US 4/Db Int/Int and	authorised drug product in	the	YES
	EU/USA/Ph.Int/Japan?	dad		NO
228	None of the above (full S Section is need	ied		
2.3 S	Drug substance			
2.3.S.1	General information S.1.1 Nomenclature			
		an an dag		
	Paste the chemical name, other names of Comments:	or codes		NO 🗌 NA
	Commenis.			
	S.1.2 Structure			
	Does the submitted documentation cove	r this subsection	YES I	NONA
	adequately?			
L			I	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

·	Guidennes for Keview and Approval of Chinical Iria	
	✓ <i>For chemicals: paste the chemical structure</i>	
	/stereochemistry.	
	✓ For biologicals: provide a brief description of the	
	predicted structure	
	Comments:	
	S.1.3 General properties	
	Does the information submitted cover this subsection adequately?	YES NO NA
	✓ For chemicals, list the physicochemical properties likely to	
	affect pharmacological or toxicological safety, eg solubility, pKa,	
	etc	
	\checkmark For biologicals, summarize the proposed mechanism of	
	action	
	Comments:	
2.3. S.2	Manufacture	
	S.2.1 Manufacturer(s)	
	Are the production sites clearly identified on GMP Certificate?	YES NO NA
	Comments:	
	S.2.2 Description of the manufacturing process and process	
	controls	
	Substance: are the manufacturing processes and their controls	└ YES └ NO └ NA
	adequately described? ✓ For chemical IMPs, brief summary of the process	
	✓ For chemical IMPs, brief summary of the process including critical steps and process controls, stereochemistry of	
	the starting materials, solvents, metal catalysts, and critical	
	reagents. Paste the flow chart of the manufacturing process	
	\checkmark For biological IMPs, provide the flow chart of the	
	manufacturing process including in-process testing, batch	
	size/scale, reprocessing. Each step should be justified	
	size/scule, reprocessing. Euch slep should be fusified	
	Comments:	l
	S.2.3. Control of materials	
	Is the control of materials adequately described?	🗌 YES 🗌 NO 🗌 NA
	\checkmark Include information on critical materials and their control	
	 ✓ For biological IMPs, include summary of source 	
	[materials], history of generation of cell substrate, the cell	
	bank system, characterization and testing, and cell	
	substrate stability and/or summary of source, history and	
	generation of virus seed material	
	 If applicable, summary of compendial and non-compendial 	
	raw materials or materials of human origin	
	Comments:	
1		

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	S.2.4 Control of critical steps and intermediates	
	<i>Is the control of critical steps and intermediates adequately</i>	YES NO NA
	described?	
	Comments:	
	S.2.5 Process validation and/or evaluation	
	Is the process validation adequately described?	YES NO NA
	Comments:	
	S.2.6. Manufacturing process development	
	Is the manufacturing process development adequately described?	YES NO NA
	 Significant differences from the manufacturing process of 	
	toxicological or previous clinical batches should be	
	summarized (if applicable)	
	\checkmark For biological IMPs: comment on comparability data (if	
	relevant)	
	~	
	Comments:	
2 2 6 2		
2.3 S.3	Characterization	
	S.3.1 Elucidation of the structure and other characteristics	
	Is the drug substance sufficiently characterised?	YES NO NA
	Summarize the methods used to characterize the product Comments	
	Comments	
	S.3.2 Impurities	
	Are impurities sufficiently characterised?	YES NO NA
	✓ For chemical IMPs: state if it complies with a Pharmacopeia	
	and if so, with which one (US, EU, JP, other) or summarize the	
	impurities from the degradation products, potential genotoxic	
	impurities of solvents and catalysts (if applicable), residual	
	solvents used for the purification of small molecules, and any	
	<i>control issues</i>	
	✓ Summarize process and product-related impurities and any	
	issues with control	
	Comments:	
2.3. S.4	Control of the drug substance	
	S.4.1 Specification(s)	
	The specifications proposed for the drug substance, including	YES NO NA
	appropriate limits, are satisfactory?	
	For those IMPs that are not controlled by a pharmacopeial	
	monograph, copy and paste the proposed specifications, tests	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Review and Approval of Clinical Trials

[
	methods and limits from the IMPD	
	Comments:	
	CA2 An abotical massachung	
	S.4.2 Analytical procedures	
	Are the analytical methods adequately described?	YES NO NA
	Comments:	
	S.4.3 Validation of analytical procedures	
	Phase I trials	U YES INO NA
	The suitability of the methods is commensurate with the stage of	
	development. The acceptance limits and parameters to validate the	
	analytical methods are presented:	
	For phase II/III trials	YES NO NA
	The suitability of methods is commensurate with the stage of	
	development and clearly explained. A summary of the validation	
	results is provided:	
	Comments:	
	S.4.4 Batch analyses	
	Data for representative batch analyses are provided for all the	U YES INO NA
	relevant manufacturing process, and for each drug substance	
	manufacturer:	
	Comment on the acceptability of the batch data provided in	
	support of the clinical trial material	
	Comments:	
	S.4.5 Justification of the specification (s)	
	The justification for the specifications is acceptable?	YES NO NA
	Summarize the critical specifications and acceptance criteria	
	Comments:	
2.3. S.5	Reference standards or materials	
	<u>Reference standard</u>	U YES INO NA
	A suitable reference standard is adequately described:	
	Comments:	
22.5.5		
2.3. S.6	Container closure system	
	The container closure system for the drug substance is properly	YES NO NA
	characterised and suitable:	
	Comments:	
<u> </u>		
2.3. S.7	Stability	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	<i>The stability for the drug substance is satisfactory and properly described for all the relevant manufacturing processes:</i>	UYES NO NA
	✓ Indicative text: amend or delete as necessary	
	✓ List of proposed shelf-life/retest period and storage conditions	
	of the drug substance.	
	✓ Summary of stability studies provided in support of the	
	proposed shelf-life.	
	✓ State number of months for which data is available.	
	 ✓ Comment on whether trends or out of spec results are 	
	observed.	
	<i>The extension of shelf-life will be made without substantial amendment</i>	U YES NO NA
	If yes, the extension will be made in accordance with a registered	YES NO NA
	protocol	
	Comments:	
3.2. P	Drug product (repeat this section for additional IMPs)	
3.3. P.1	Description and composition of the investigational medical produ	ct
	The description and composition are adequate:	YES NO NA
	Provide the qualitative and quantitative composition of the IMP	
3.3. P.2	Pharmaceutical development	
	The pharmaceutical development is adequately described:	YES NO NA
	Comments:	
3.3. P.3	Manufacture	
	P.3.1 Manufacturer(s)	
	<i>The manufacturing sites are clearly identified:</i>	YES NO NA
	Comments:	
	P.3.2 Batch formula	
	<i>The batch formula is appropriately described:</i>	YES NO NA
	Comment on the batch size proposed	
	Comment on the buich size proposed Comments:	
	comments.	
	P.3.3 Description of the manufacturing process and process	
	P.3.3 Description of the manufacturing process and process controls	
	controls The manufacturing process and process control are adequately	YES NO NA
	controlsThe manufacturing process and process control are adequately described:✓✓Add a brief summary of the manufacturing process including	YES NO NA
	 controls The manufacturing process and process control are adequately described: ✓ Add a brief summary of the manufacturing process including critical steps 	YES NO NA
	controls The manufacturing process and process control are adequately described: ✓ Add a brief summary of the manufacturing process including critical steps ✓ and in-process controls or paste the flow chart of the	YES NO NA
	 controls The manufacturing process and process control are adequately described: ✓ Add a brief summary of the manufacturing process including critical steps 	YES NO NA

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	P.3.4 Controls of critical steps and intermediates	
	<i>The controls of critical steps and intermediates are adequately</i>	YES NO NA
	described:	
	Comments:	
	P.3.5 Process validation and/or evaluation	
	The validation processes are adequately described:	YES NO NA
	If relevant, confirm if the process validation for non-standard	
	sterilization	
	and manufacturing processes are provided	
3.2. P.4	Control of excipients	
	P.4.1 Specifications	
	For excipients not described in current pharmacopoeias	YES NO NA
	The specifications and acceptance criteria provided are	
	appropriate:	
	Comments:	
	P.4.2 Analytical procedures	
	The analytical procedures are adequately described:	YES NO NA
	Comments:	
	P.4.3 Validation of the analytical procedures	
	The analytical procedures are adequately validated:	YES NO NA
	Comments:	
	P.4.4 Justification of the specifications	
	The justification provided for the specifications of excipients and	YES NO NA
	their limits is satisfactory:	
	Comment on the acceptability of the batch data provided in	
	support of the	
	clinical trial material	
	Comments:	
	P.4.5 Excipients of animal or human origin	
	<i>The IMP contains excipients of animal origin:</i>	
	Safety information on transmissible spongiform encephalopathies (TSE) is provided and deemed satisfactory:	U YES NO NA
	Comments:	
	P.4.6 Novel excipients	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	Excipients are appropriately controlled:	YES NO NA
	Confirm compliance for excipients described in the pharmacopeia.	
	For those not described therein, check if adequate information on	
	quality control was provided	
3.2. P.5	P.5 Control of the drug product	
	P.5.1 Specifications	
	Satisfactory specifications for the drug product, including	YES NO NA
	appropriate limits, are proposed:	
	Copy and paste the proposed drug product specifications,	
	including limits,	
	from the IMPD	
	P.5.2 Analytical procedures	
	Are the analytical methods adequately described?	YES NO NA
	Comments:	
	P.5.3 Validation of analytical procedures	
	Phase I trials	
	The suitability of the methods is commensurate with the stage of	\square YES \square NO \square NA
	development. The acceptance limits and parameters to validate the	
	analytical methods are presented:	
	unuryrieur memous are presenteu.	
	For phase II/III trials	
	The suitability of methods is commensurate with the stage of	\square YES \square NO \square NA
	development and clearly explained. A summary of the validation	
	results is provided:	
	Comments:	
	Comments.	
	P.5.4 Batch analyses	
	Data for representative batch analyses are provided for all the	YES NO NA
	relevant manufacturing process, and for each drug product	
	manufacturer:	
	Comments:	
	Comments.	
	P.5.5 Characterizations of impurities	
	<i>The information provided for impurities is acceptable:</i>	YES NO NA
	Discuss additional impurities/degradants that are not part of the	
	drug substance and whether they are properly controlled by the	
	drug product specification	
	anag produce specification	
	Comments:	l
	Commentas.	
	P.5.6 Justification of specification(s)	
	<i>The justification for the drug product specifications and limits is</i>	YES NO NA
	acceptable	
	Comments:	l
	Commentas.	
32 P6	Reference standards or materials	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	Reference standard A suitable reference standard is adequately described:	UYES NO NA
	Comments:	
3.2. P.7	P.7 Container closure system	
	<i>The container closure system for the drug product is properly</i>	YES NO NA
	characterised and suitable:	
	Comments:	
3.2. P.8	Stability	
	P.8.1 Stability summary and conclusions	
	P.8.2 post-approval stability protocol and stability	
	commitment	
	P.8.3 Stability data	
	The drug product has undergone appropriate stability tests:	U YES NO NA
	✓ Indicative text: amend or delete as necessary	
	 Proposed shelf-life and storage conditions of the IMP? 	
	 Summary of stability studies provided in support of the 	
	proposed shelf-life	
	 (delete/amend columns as appropriate). State the number of months for which data are available. 	
	 Comment whether trends or out of specifications results were 	
	observed.	
	<i>The extension of shelf-life will be made without substantial</i>	YES NO NA
	amendment:	
	If yes, extension to be made in accordance with a registered	YES NO NA
	protocol:	
	Comments:	
	Comparator (comparator 1, comparator 2 etc – replicate indivi	idual sections of the
	review form, 2.S and 2.P as required)	
	The data provided for the comparator are acceptable:	YES NO NA
	For modified authorized comparators: add a description and	
	justification of the modification	
	Comments:	
	Placebo (PL1, PL2 etc, - replicate this section as required)	·
	The information provided on the placebo is acceptable: Or (delete	🗌 YES 🗌 NO 🗌 NA
	if not applicable):	
	No information was provided, but this is acceptable because the	
	product has the same composition as the IMP. It's manufactured	
	by the same manufacturer and is not sterile	
	Summary of information provided and its acceptability:	
	<i>P.1 Description and composition</i>	
	P.2 Pharmaceutical development	
	P.3 Manufacture	
	P.4 Control of excipients	
	P.5 Control of placebo product	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	- I
P.6 Container closure system	
P.7 Stability	
Comments:	
Auxiliary medical products– replicate the individual sections of	of the review form, 3.S and
3.P as required	,
The quality data provided for non-authorised auxiliary medical	YES NO NA
products are acceptable	
Labelling	
Is the proposed labelling in line with national requirements?	YES NO NA
Comments:	
Blinding	
Refer to the statistical methodology given in the clinical trial	
protocol	
Reviewer's overall conclusions on the quality part	
The quality data are acceptable:	YES NO NA
Supplementary information has to be provided	YES NO NA
Refer to the requests for additional information	YES NO NA

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-VIII: Template for review of non-clinical data



Rwanda Food and Drugs Authority

Nyarutarama Plaza, KG 9 Avenue P.O. Box: 1948 Kigali - Rwanda Email: <u>info@rwandafda.gov.rw</u> website: <u>www.rwandafda.gov.rw</u> QMS N°: FDISM/PVSM/FMT/006 Revision No: 01 Effective Date: 11/04/2023

Review of non-clinical data

Date of the submission (cover letter)			
Date of receipt (Rwanda FDA stamp)			
Application Reference Number	NNNN/YYYY (eg. 00000/2023)		
Reviewers and Review Date			
First Reviewer	Name	Date	Signature
Second Reviewer			
Type CT Application	New Application	(CTA)	
	Amendment Appl	lication (CTAA)	
Title of Clinical Trial Application			
Protocol Reference Number			
Protocol Version Number (if applicable)			
Name and complete address of CTA			
Applicant			
Names of Principal Investigator			
Names of Co-Investigator			
Names of Sponsor and address			
(If applicable)			
Name and address of the Contract research			
Organization (s) (CRO) where the clinical			
studies proving efficacy and safety of the			
product were conducted.			
Phase of the Trial (if applicable)			
Number of Participants			
Number of Clinical Trial Site(s)			
Duration of Clinical Trial			
Name of Investigational Product (IP)			
Proprietary Product Name (if relevant)			
International Non-proprietary Name (INN)			
of the Active Pharmaceutical Ingredient			
(API), strength, pharmaceutical form.			
Name (s) and complete address (es) of the			
manufacturer (s) of the Investigational			

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	(s), including the final product f different from the manufacturer.		
) and complete address (es) of the		
× .	turer (s) of the Investigational		
	(s), including the final product		
-	f different from the manufacturer.		
	ational Product Therapeutic		
Indicatio	-		
	ational Product Route of		
Adminis			
Investiga	ational Product storage Information		
	Storage consideration		
Overall	Conclusion of the CTA Review	ACCEPTED	
		ADDITIONAL DATA REC	QUESTED
		REJECTED	
Points to	be communicated with the		
Clinical	Trial Applicant:		
Please c	opy all relevant information to be		
commun	icated to the CT applicant in the		
	nding letter and save it accordingly		
	Trial Commitments (if any)		
REVIE	W OF NON-CLINICAL DATA or 1	PRECLINICAL DATA (Phase]	[& II)
1.0	Introduction		
	Provide a brief overview of the prec	linical package and any relevant	preclinical issues
	identified in previous assessments		
	IMPs with an MA: indicate if the IM	8 8 8	ē
	authorization, of if the population/de		ration is different. If the
	latter, describe the supporting inform	mation in the relevant sections	r
2.0	Pharmacology		
	2.1 Primary pharmacodynamics		
	The pharmacology studies provide t	he pharmacological basis for	YES NO NA
	the proposed trial Were relevant in vitro and/or in vivo	models studied?	YES NO NA
	Is the intended pharmacological effe		YES NO NA
	exposure?	ει επρείτεια possible di clinical	
		or metabolites identified?	YES NO NA
	Were pharmacologically active major metabolites identified? YES NO NA Is the IMP a first-in-class compound? YES NO NA		
	<i>Provide a brief outline of the in vivo</i>		
	pharmacodynamics and the results:	, in the studies perjoi med to eral	unite primery
			1
	2.2 Secondary pharmacodynamics		
	The studies described in this section		YES NO NA
	Are off-target effects expected / poss	sible at clinical exposure?	YES NO NA
	Comments:		

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	2.3 Safety pharma						
	System	Study type	Issues ia		Major findings		
	Cardiovascular		YES	□ NO			
	Respiratory		YES	□ NO			
	CNS			NO			
	Other			NO			
	Did the safety pharm	nacology studies identi		concerns?	YES NO NA		
		ns of exposure exist for					
	Comments:						
	2.4 Pharmacodyna	mic drug interactions					
	Have potential phar	macodynamics drug in	teractions ide	ntified	YES NO NA		
	Describe briefly any	[,] in vitro/in vivo studies	s performed a	nd their			
	results if any						
	Comments:						
3.0	Pharmacokinetics						
	3.1 Methods of analysis						
	Are the methods of analysis and their sensitivities adequate?			YES NO NA			
	Comments:						
	3.2 Absorption, dist	ribution, metabolism &	excretion		YES NO NA		
	System	Issues identified		Findings			
	Absorption	YES NO	NA	0			
	Distribution	YES NO	NA				
	Metabolism	YES NO	NA				
	Excretion	YES NO	NA				
	Do the ADME studi	es identify significant c	oncerns?		YES NO NA		
		polites were identified			YES NO NA		
	0	bolites were identified			YES NO NA		
	Add a brief description of the studies performed and the results. A c						
	4.4.3, 4.4.5, and 4.4.6 (toxicokinetic) is enough						
	Comments:						
		ic drug interactions (enzymes tra	Isnorter			
	other)	ac ar ag miter actions (sporter,			
L	Target evaluated	Interaction identif	ìed	Findings	1		
	Enzyme inhibition	YES NO	NA				
	En2yme innibilion		1111				

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Review and Approval of Clinical Trials

	Brief description of any studies performed. The results should be presented in the tablets:								
	exposure	gins of exposure exi	isi jor planned c	unical					
		oxicities identified?		liniaal			YES] NO [] NO [NA NA
								-	_
)						
	appropriate								
	(delete as								
			/MNT	D					
	Species	Dose/Route	NO(A) OEL)ĽL/L	Major	111	luings		
	4.2. Single dose to	*			N/	£	. di		
		•••							
l									
	be discussed in this section:								
	relevant guidelines (ICH M3 (R2), S6 (R1), S9) used, and any deviations for any guidelines. Any study-specific guidelines should be discussed in this section:								
I									
I		Describe briefly the preclinical toxicity studies performed, the							
		es were sufficiently well-designed					YES 🗌] NO [NA
	The studied specie	es show similar PK to	o humans				YES	NO [NA
	0 1	es show similar pharm		nan			YES] NO [NA
	· · · · ·	Toxicologically relevant animal species studied					YES	NO	NA
1.0		s selection/study des	sign						
4.0	Toxicology								
	the results:								
		ny additional invitro	/invivo studies p	erforme	d and				
	Do these studies in						YES	NO	NA
	Were other PK stu		//				YÉS] NO [NA
	_	advertent germline			-		-	mit	
	3 1 Othow phawes	cokinetic studies (e.	a DK of mataka	lite nor	al avain	ia	nts com	mia	
			1 5						
		ne invitro/invivo stud			ss the re	esu	lts:		
	1	ractions have been h mation is included in	0 0	0	75		YES	NO	NA
		lrug interactions is in					YES		NA
	Co-pathways		O NA	·		<u> </u>	VEC		.
	Transporter								
	<i>Enzyme induction</i>								

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

4.3 Repeat-dose toxicity				
Species	Dose/Route	NO(A)EL/L OEL /MNTD (delete as appropriate)		lajor findings
Do sufficient margins of exposition	ure exist for pl	anned clinical		YES NO NA
exposure	auna aut tha ar	an agod trial de	nation	
Does the duration of treatment Brief description of any studies				YES NO NA
4.4 Genotoxicity				
Type of test/study	Test system		Results	. — . —
Gene mutations in bacteria			Equivo	tive 🗌 Negative 📃 cal
In Vitro Mammalian assay			Posi Equivo	tive 🗌 Negative 🗌 cal
In vivo genotoxicity test			Posi Equivo	tive 🗌 Negative 🗌 cal
Additional assays				itive 🗌 Negative 🗌
Do the submitted data indicate	genotoxic pote	ential?	I	YES NO NA
Comments:				
4.5 Carcinogenicity				
Do studies identify potential for				YES NO NA
Do sufficient margins of exposi exposure?				U YES NO NA
4.6 Reproductive and develop				
System	Toxicities ide	~	Finding	38
<i>Fertility and early embryonic development</i>	YES N	IO 🗌 NA		
Embryo-fetal development	YES N	IO 🗌 NA		
Prenatal and postnatal	YES N	IO 🗌 NA		

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

development, i	0					
maternal funct			[[
	nargins of expo	sure exist for planned clinical		YES NO NA		
<i>Comments:</i>	exposure?					
Comments.						
4.6.1 Juvenile	toxicity studie	S				
The studies uti	lised animals ir	the appropriate age range		YES NO NA		
		nal/enhanced juvenile toxicities	[YES NO NA		
Do sufficient n exposure?	nargins of expo	sure exist for planned clinical	[YES NO NA		
Comments:						
4.6.2 Other st	udios					
	ntified potentia	1 toxicities	1	YES NO NA		
	• •	sure exist for planned clinical		YES NO NA		
exposure?	ιαι gins 05 επρο	sure exist for planned etimeat				
Comments:						
		contraception measures	1 [
Investigational medicinal prod		inical data summary				
medicinal proc	fetotox	ted/ demonstrated teratogenic of ic effects				
	Genoto					
		cient data				
		strated embryo-fetotoxic effects, do not seem relevant to the CT pants				
		ent data and no indication of rish	k [
Comparator		inical data summary				
Investigational	Suspec	ted/ demonstrated teratogenic of	r [
medicinal		ic effects				
products/Auxil	iary Genoto	xic				
	00	cient data				
		strated embryo-fetotoxic effects,				
		do not seem relevant to the CT				
	particij		, , r			
	10	ent data and no indication of rish	К []			
		inical data summary				
		ted/ demonstrated teratogenic of ic effects				

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Guidelines for Review and Approval of Clinical Trials

	1				
		Genotoxic			
	4 7 7	1	1	demonstrated/	
		ommendations related to cont		suspected	
	1 0 1 0	clinical trials" the risk of ter		possible	
	•	the non-clinical data is consi	aerea (piease tick	unlikely	
	one) Comment:				
	Comment:				
	4.7 Local tolerance				
		lies indicate a potential for lo	ocal toxicity?	YES NO NA	
	Comments:	iles indicate à potential for te	jear toxicity.		
	4.8 Other toxicity stu	dies			
	Dedicated Study	Toxicities identified	Findings		
	Phototoxicity	YES NO NA	0		
	Tissue cross	YES NO NA			
	reactivity				
	Antigenicity	YES NO NA			
	Immunotoxicity	YES NO NA			
	Dependence	YES NO NA			
	Metabolites	YES NO NA			
	Impurities	YES NO NA			
	Other	YES NO NA			
	Comments:				
_		-			
5.	Additional Considerations				
		T • 1			
	5.1 First in Human Trials				
	Is the starting dose adequately justified?				
	Are the dose steps ad				
		adequately justified?		YES NO NA	
	Assessor's comment.	-			

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

ANNEX-IX: Template for Review of trial amendment



Rwanda Food and Drugs Authority

Nyarutarama Plaza, KG 9 Avenue P.O. Box: 1948 Kigali - Rwanda Email: <u>info@rwandafda.gov.rw</u> website: <u>www.rwandafda.gov.rw</u>

Review of trial amendment

QMS N°: FDISM/PVSM/FMT/007 Revision No: 01 Effective Date: 11/04/2023

Date of the submission (cover letter)				
Date of receipt (Rwanda FDA stamp)				
Application Reference Number	NNNN/YYYY (eg. 00000/2023)			
Reviewers and Review Date				
First Reviewer	Name	Date	Signature	
Second Reviewer				
Type CTAA	Clinical Protoc	ol-Related Amend	ment	
	Investigational	Products Related	Amendment	
Title of Clinical Trial Application				
Protocol Reference Number				
Protocol Version Number (if applicable)				
Name and complete address of CTA				
Applicant				
Names of Principal Investigator				
Names of Co-Investigator				
Names of Sponsor and address				
(If applicable)				
Name and address of the Contract research				
Organization (s) (CRO) where the clinical				
studies proving efficacy and safety of the				
product were conducted.				
Phase of the Trial (if applicable)				
Number of Participants				
Number of Clinical Trial Site(s)				
Duration of Clinical Trial				
Name of Investigational Product (IP)				
Proprietary Product Name (if relevant)				
International Non-proprietary Name (INN)				
of the Active Pharmaceutical Ingredient				
(API), strength, pharmaceutical form.				

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

Name (s) and complete address (es) of the manufacturer (s) of the Investigational product (s), including the final product	
C/ C	
product (s), including the final product	
produce (b), meruding the multiproduce	
release if different from the manufacturer.	
Name (s) and complete address (es) of the	
manufacturer (s) of the Investigational	
product (s), including the final product	
release if different from the manufacturer.	
Investigational Product Therapeutic	
Indications	
Investigational Product Route of	
Administration	
Investigational Product storage Information	
Special Storage consideration	
Overall Conclusion of the CTAA Review ACCEPTED	
ADDITIONAL DAT	A REOUESTED
Points to be communicated with the	
Points to be communicated with the	
Clinical Trial Applicant:	
Clinical Trial Applicant:	
Clinical Trial Applicant : <i>Please copy all relevant information to be</i> <i>communicated to the CT applicant in the</i>	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly	
Clinical Trial Applicant : <i>Please copy all relevant information to be</i> <i>communicated to the CT applicant in the</i>	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly	
Clinical Trial Applicant:Please copy all relevant information to becommunicated to the CT applicant in thecorresponding letter and save it accordinglyClinical Trial Commitments (if any)	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment	
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment	nted Amendment ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment Investigational Product	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relational Product CURRENT ACCEPTED	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relate □ Investigational Product CURRENT ACCEPTED INFORMATION	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relate □ Investigational Product CURRENT ACCEPTED INFORMATION	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Clinical Protocol-Relate □ Investigational Product CURRENT ACCEPTED INFORMATION	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment CURRENT ACCEPTED INFORMATION SUMMARY OF AMEN Investigational Product Investigational Product Investigational Product	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Investigational Product CURRENT ACCEPTED INFORMATION The rationale of the amendment (s)	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment CURRENT ACCEPTED INFORMATION SUMMARY OF AMEN Investigational Product Investigational Product Investigational Product	ets Related Amendment
Clinical Trial Applicant: Please copy all relevant information to be communicated to the CT applicant in the corresponding letter and save it accordingly Clinical Trial Commitments (if any) REVIEW OF AMENDMENTS Type of Trial Amendment □ Investigational Product CURRENT ACCEPTED INFORMATION The rationale of the amendment (s)	ets Related Amendment DMENTS

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

	Reviewer's Comments:	
	Is the Amendment to the protocol? If Yes specify the changes made to the protocol	YES NO
	Reviewer's Comments:	
	<i>Is an amendment to information in the CT application form or appended documents?</i>	YES NO
	Reviewer's Comments:	
	<i>Is this amendment concerns mainly urgent safety measures already implemented?</i>	
	Do changes affect the safety or integrity of trial Participants?	UYES U NO
	Do changes affect the conduct or management of the trial Do changes affect the interpretation of scientific documents/value of	YES NO YES NO
	the trial Does the change in Information on the temporary halt of trial?	
	If YES does the Treatment been stopped? Reviewer's Comments:	
	(Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendments, Justification for a temporary halt of the trial, The proposed management of patients receiving treatment at time of the halt, The consequences of the	
	temporary halt for the evaluation of the results and for overall risk- benefit assessment of the investigational medicinal product)	
	<i>Change or addition of principal investigator(s), coordinating investigator?</i>	YES NO
	Change/addition of Clinical trial site(s) Reviewer's Comments:	YES NO
	Have relevant supporting documents been provided? If No ask them. Reviewer's Comments:	YES NO
2	Amendment related to Investigational Products if applicable	
	The change affect the entire manufacturing process of the investigational product	YES NO
	Reviewer's Comments:	
	<i>The change involve the change manufacturing s the investigational product.</i>	YES NO
	Reviewer's Comments:	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023

<i>Do changes in strength or dosage form of the investigational products?</i>	
Reviewer's Comments:	
<i>Do changes in extension of reduction in shelf life of Investigational products?</i>	
Reviewer's Comments:	
Do changes on investigational products affect its quality, safety or efficacy?	
Reviewer's Comments:	
Other changes related investigational products	
Reviewer's Comments:	
Do relevant supporting documents related to amendments submitted? If NO request the PI/Sponsor to submit all necessary documents	
Reviewer's Comments:	
General Reviewer's Comments:	

Doc. No.: FDISM/PVSM/GDL/008	Revision Date: 03/04/2023	Review Due Date: 10/04/2026
Revision No.: 01	Approval date: 05/04/2023	Effective Date: 11/04/2023